Rebamipide Protects Colonic Damage Induced by Trinitrobenzene Sulfonic Acid (TNBS) via Down-Regulation of TNF-alpha IL-1beta and ICAM-1.
- Author:
Yeun Ha KIM
1
;
Sung Jung KIM
;
Ho Geun HWANG
;
Suk Chei CHOI
;
Yu Rim KIM
;
Kyung Suk KIM
;
Chul KIM
;
Deok Hwa CHOI
;
Jung Taek OH
;
Gang Deuk KIM
;
Hye Won KIM
;
Chang Duk JUN
;
Chun Jeih RYU
;
Yeun Tai CHUNG
;
Min Kyu CHOI
;
Jay Min OH
Author Information
1. Department of Anatomy, Wonkwang Medical Science Institute, Korea. jmoh@wonkwang.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Rebamipide;
IBD;
TNBS;
TNF-alpha;
IL-1 beta;
ICAM-1
- MeSH:
Animals;
Body Weight;
Colitis;
Colon*;
Down-Regulation*;
Edema;
Humans;
Inflammation;
Inflammatory Bowel Diseases;
Intercellular Adhesion Molecule-1*;
Interleukin-1beta;
Mice;
Mucous Membrane;
Phenobarbital;
Tumor Necrosis Factor-alpha*;
Ulcer
- From:Korean Journal of Anatomy
2004;37(2):149-155
- CountryRepublic of Korea
- Language:English
-
Abstract:
During inflammation of the colon, cells of the gut mucosa produce or express numerous inflammatory mediators, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1 beta), and intercellular adhesion molecule 1 (ICAM-1). These mediators have been implicated as contributory factors to the inflammatory process, which results in colitis during inflammatory bowel disease (IBD). Rebamipide is an anti-gastric ulcer drug with anti-inflammatory properties in vivo and in vitro. The effects of Rebamipide on IBD have not been largely evaluated. Therefore, this study investigated the potential of Rebamipide to regulate the production of inflammatory mediators such as TNF-alpha, IL-1beta, and ICAM-1. Mice with trinitrobenzene sulfonic acid (TNBS)-induced colitis (IBD animal model), were treated intrarectally with 2 mM Rebamipide. Body weight, macro- and micro-histological scores, and activity were evaluated. As an index of tissue edema, the thickness of the colonic wall was measured between the serosal surface and the luminal surface of the mucosa. TNF-alpha, IL-1 beta, and ICAM-1 were detected by immunohistochemical staining. Rebamipide treatment of mice exhibiting TNBS-induced colitis dramatically improved the clinical and histopathological findings of inflammation. In addition, Rebamipide suppressed TNF-alpha, IL-1 beta, and ICAM-1 expression in TNBS-treated animals. Taken together, these findings suggest that Rebamipide is a potential therapeutic agent for treating patients with IBD.
